Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors

Journal of Laboratory and Clinical Medicine

Volumn 139, Issue 4, 2002, Pages 234-243

  Hu, Ke Qin ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ANIMAL; DRUG ANTAGONISM; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LIVER NEOPLASMS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036014815     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2002.122281     Document Type: Article

References (82)

1. Malignant neoplasms of the liver
2. Hepatic tumors and cysts
3. Hepatocellular carcinoma
4. Changing incidence of hepatocellular carcinoma in Japan
5. Increase in primary liver cancer in the UK, 1979-94
6. Trends in primary liver cancer
7. Rising incidence of hepatocellular carcinoma in the United States
8. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the Unites States
9. Epidemiology of hepatocellular carcinoma
10. Risk factors for the rising rates of primary liver cancer in the United States
11. Hepatitis B virus: The major etiology of hepatocellular carcinoma
12. Hepatitis B-related sequelae: Prospective study in 1400 hepatitis B surface antigen positive Alaska Native carriers
13. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
14. Risk factors for hepatocellular carcinoma among patients with chronic liver disease
15. The long-term outcomes of patients with compensated HCV-related cirrhosis and history of parenteral exposure in the United States
16. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
17. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma
18. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice
19. Strong, sustained hepatocellular proliferation provides hepatocarcinogenesis in hepatitis B surface antigen transgenic mice
20. Hepatdnaviral hepatocarcinogenesis: In situ visulization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks
21. Subcellular localization of hepatitis B antigen in relation to hepatocytes regeneration in chronic hepatitis B
22. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease
23. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection
24. Pathogenesis of hepatocellular carcinoma
25. Hepatocellular carcinoma
26. Histological evaluation of hepatocellular carcinoma with special reference to small early stage tumors
27. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma
28. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsy
29. Early stages of multistep hepatocarcinogenesis: Adenomatous hyperplasia and early hepatocellular carcinoma
30. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
31. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
32. Evaluation of cyclooxygenase-2 inhibitor for potential chemoproventive properties in colon carcinogenesis
33. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
34. Aspirin use and potential mechanisms for colorectal cancer prevention
35. The "aspirin" of the new millennium: Cyclooxgenase-2 inhibitors
36. Biochemistry of cyclooxgenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia
37. Evidence for involvement of NF-kappa B in the transcriptional control of COX-2 gene expression by IL 1-beta
38. Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: Attenuation by dexamethasone and NSAIDs
39. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat
40. Transforming growth factor beta1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons
41. Growth stimulation and induction of epithelial growth factor receptor by over expression of cyclooxygenases 1 and 2 in human colon carcinoma cells
42. Malignant tumors of the colon
43. Chemoprevention of colorectal cancer
44. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
45. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
46. Expression of cyclooxygenase-1 and -2 in human colon cancer
47. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis
48. Prostaglandin E2 levels and lymphocyte subsets in portal venous drainage of colorectal cancers
49. The role of cyclooxygenases in inflammation, cancer, and development
50. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
51. Suppression of intestinal polyposis in APC delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
52. Chemopreventive activity of celecoxib, a specific cyclooxygenase 2 inhibitor, against colon carcinogenesis
53. Chemoprevention of spontaneous intestinal adenomas in the APC Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
54. Effect of NSAIDS on proliferation of gastric cancer cells in vitro: Possible implication of cyclooxygenase-2 in cancer development
55. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action
56. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a cyclooxygenase-2 inhibitor, NS-398
57. A cyclooxygenase-2 (COX-2) selective, non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: Regulation of COX-2 by butyrate
58. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
59. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action
60. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells
61. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
62. Cyclooxgenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
63. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
64. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells
65. Effect of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer by a prostaglandin-independent pathway
66. A nuclear receptor to prevent colon cancer
67. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines
68. Effects of flurbiprofen enantimers on pain-related chemosomatosensory evoked potentials in human subjects
69. Min/+ mouse model: Implications for prophylaxis and treatment of colon cancer
70. Prostate cancer treatment by R-flurbiprofen in the tramp mouse
71. Multi dose phase I-II trial of E-7869 in prostate cancer patients: Safety and time to PSA progression
72. Colorectal cancer risk, chronic illness, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
73. Aspirin use and reduced risk of fetal colon cancer
74. A hypothesis: Nonsteroidal anti-inflammatory drugs reduced the incidence of large bowel cancer
75. Aspirin use and the risk of for colorectal cancer and adenoma in male health professionals
76. Sulindac for polyposis of the colon
77. Effects of long-term sulindac therapy on colonic polyposis
78. Increased expressin of COX-2 in nontumorous liver tissue is associated with shorter disease-free survival in patient with hepatocellular carcinoma
79. Cyclooxgenase-2 is induced by phorbol ester in transformed and CYP2E1-expressing hepatocytes
80. Characterization of inhibited growth of cyclooxygenase-2 (COX-2) expressing human hepatoma cells by a selective COX-2 inhibition (NS-398)
81. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell line